Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery.
01.
We harness light to control biology with unmatched precision.
02.
We apply the latest chemistry tools to optimize our drug discovery.
03.
We power our platform with an AI engine fueled by differentiated datasets.
We are advancing a pipeline of novel small molecule therapeutics by unraveling complex biology with optogenetics, chemistry, and AI. Built on pioneering science from our scientific co-founder, Prof. Jim Collins at MIT, and powered by a world-class team of innovators, we are pushing the boundaries of how biology can be understood and engineered.
Our discoveries have been repeatedly featured in Nature, Nature Aging, Nature Protocols, and Cell, underscoring the impact of our approach.
Today, our mission targets age-related diseases, while our ultimate ambition is far bolder: to fundamentally rewrite the biology of aging.
In this landmark Cell publication, we unveil our first-of-a-kind optogenetic screening platform, which unlocks a novel mode of drug discovery by enabling tunable, millisecond- and micron-level control over previously intractable biological systems.